![]() “In the 21st century, people shouldn’t be looking through microscopes, manually counting cells,” said Itai Hayut, co-founder and CEO of Scopio. ![]() Scopio brings the remote-work revolution to hematology and cell morphology, enabling a new subfield of telehematology. The Covid-19 pandemic has accelerated this trend of doing as much as possible remotely. Remote diagnostic healthcare has grown in the last decade, with subfields like teleradiology enabling experts to review images from anywhere in the world. More AI solutions are under development, including for bone marrow aspirates (BMA). ![]() The company’s FDA-cleared and CE-marked Full-Field Peripheral Blood Smear (Full-Field PBS) Application supports detection, pre-classification and quantification for blood cells. With high-quality digital images of slides now available for the first time, Scopio has also developed AI-based decision-support solutions to analyze them. Once scanned, Scopio images can be accessed anywhere, freeing hematopathologists and clinicians from the lab and the microscope so they can review and collaborate wherever they are. The full digitized slide can then be explored, scrolled and zoomed at 100X magnification (interactive demo here) to get ultra-sharp views of individual cells, visible in the full context of the sample. Scopio’s custom-designed “X100” digital slide-scanning device uses computational photography to produce ultra-high-resolution images of entire sample slides. Scopio has created a full end-to-end workflow to digitize and analyze blood samples. But for us it all begins with high-quality digital imaging data,” said Scopio co-founder and CEO Itai Hayut. ![]() “Deep Learning can analyze hundreds of times more healthcare data from a patient, supporting physician decisions and detecting conditions like cancers, anemias, and bleeding disorders, as well as infections and allergies. Even when snapshots of a few cells can be digitized, the images are removed from its full context, forcing investigators to keep the slide and microscope on hand. However, one of the most common tests, the Peripheral Blood Smear review, is still predominantly conducted by a human looking at a sample under a microscope, classifying cells by type, counting them and hunting abnormalities that could mean cancer or other diseases. The Series C round included OurCrowd, Aurum Ventures, Mizrahi-Tefahot Bank Invest and Ilex Medical, with the participation of strategic investors operating in the field and existing investors.īlood tests are among the most frequent medical procedures in the world, with billions conducted every year. ![]() Scopio Labs has announced a $50M investment for its end-to-end hardware and software platform for digitizing, quantifying and analyzing hematology and other digital cytology samples. LC-MS innovation: Improve analytical accuracy Which microbioreactor modules are best for you Which solid support is right for your oligo synthesis?
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |